Eikon and Veradermics Announce IPO Targets Amid Biotech Market Optimism
Veradermics, a hair loss biotech, set terms for a $200 million IPO on January 28, 2026, offering 13.4 million shares at $14-$16, planning to list on NYSE as MANE to fund VDPHL01, an extended-release minoxidil in Phase 3 trials.12
Eikon Therapeutics, a cancer-focused biotech, targets up to $317.7 million in its IPO with 17.65 million shares at $16-$18, aiming for a $908.2 million valuation, to list on Nasdaq as EIKN, funding clinical assets like EIK1001 for melanoma and NSCLC.1346
Both follow Aktis Oncology's successful $318 million IPO earlier in January 2026, signaling cautious optimism in the biotech IPO market after a prior drought.134
Veradermics' VDPHL01 is in late-stage trials for pattern hair loss; Eikon's pipeline includes TLR7/8 agonists and PARP1 inhibitors.123
Sources:
1. https://www.biospace.com/business/veradermics-eikon-eye-public-market-debut-as-ipo-tap-opens
2. https://www.renaissancecapital.com/IPO-Center/News/116528/Hair-loss-biotech-Veradermics-sets-terms-for-$200-million-IPO
3. https://www.fiercebiotech.com/biotech/eikon-next-line-ipo-funds-set-bankroll-clutch-clinical-cancer-drugs
4. https://ng.investing.com/news/stock-market-news/eikon-therapeutics-targets-9082-million-valuation-in-us-ipo-93CH-2309393
6. https://pharmaphorum.com/news/eikon-prices-its-ipo-seeking-raise-318m